Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cemiplimab consolidation after induction therapy and local radical treatment for oligometastatic NSCLC
NL-OMON60233Phase 3Active, not recruiting
- Sponsor
- European Organisation for Research and Treatment of Cancer
- Start
- Jun 2025
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of cemiplimab in non-small cell lung cancer (NSCLC), sponsored by European Organisation for Research and Treatment of Cancer. Primary endpoint: Progression-free survival. Started Jun 2025; status: active, not recruiting.
02
Drugs
cemiplimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NL-OMON60233.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60233.